Eucrates Biomedical Acquisition EBIT

Eucrates Biomedical Acquisition (EUCR) currently reports a EBIT of $-700K as of December 2022. That compares with $-1M in the prior-year period — up 30.3% year over year. That is above the sector sector average of $-22M. Use the charts on this page to explore Eucrates Biomedical Acquisition's EBIT history and peer comparisons.

Eucrates Biomedical Acquisition's EBIT increased from $-1M to $-700K — a 30.3% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eucrates Biomedical Acquisition's EBIT of $-700K is higher than the its sector sector average of $-22M. That is roughly 96.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eucrates Biomedical Acquisition reported $-700K in EBIT as of December 2022. That compares with $-1M in the prior-year period — up 30.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-700K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-22M. From there, open related valuation or income-statement pages for Eucrates Biomedical Acquisition, and consider following EUCR for alerts when major investors trade the stock.